Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BT7480 |
Synonyms | |
Therapy Description |
BT7480 is a bicyclic peptide CD137 agonist therapy that targets Nectin-4-expressing cells, potentially leading to immune cell activation and tumor regression (PMID: 34725211). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BT7480 | BT 7480|BT-7480 | BT7480 is a bicyclic peptide CD137 agonist therapy that targets Nectin-4-expressing cells, potentially leading to immune cell activation and tumor regression (PMID: 34725211). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05163041 | Phase Ib/II | BT7480 BT7480 + Nivolumab | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Recruiting | USA | GBR | 0 |